Evidence map›Paper›PMID 32658335›Full record

ReviewImmunological reviews2020

The role of host genetics in the immune response to SARS-CoV-2 and COVID-19 susceptibility and severity.

Inna G Ovsyannikova, Iana H Haralambieva, Stephen N Crooke, Gregory A Poland, Richard B Kennedy

Registry-linked trialOpen access · bronzeAbstract readReview
In one paragraph

Review in Immunological reviews, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04750330 (Mitochondrial DNA and Nuclear SNPs to Predict Severity of COVID-19 Infection), which is not on this map. Cited by 141 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
141citing papers in PubMed, 5 pooled it
5.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04750330 completednot on this mapstarted 2021, after this paper: background citation

Mitochondrial DNA and Nuclear SNPs to Predict Severity of COVID-19 Infection

TypeobservationalSponsorMaastricht UniversityRan2021 to 2023Enrolled394ConditionsCovid19
3 · Its place in the literature

Who cites it

141 citing papers in PubMed, 5 syntheses or guidelines pooled it, 266 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Apoptotic body-encapsulated zinc-dopedMaterials today. Bio · 2026
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Evaluation of the IMPROVE-DD score in COVID-19 patients submitted to venous thromboembolism investigation at a hospital in Brazil.Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia · 2025
    Article
  19. TheInfectious disorders drug targets · 2025
    Article
  20. Article

81 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Inna G OvsyannikovaMayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, MN, USA.
Iana H HaralambievaMayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, MN, USA.
Stephen N CrookeMayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, MN, USA.
Gregory A PolandMayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0001-5057-4457
Richard B KennedyMayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, MN, USA.
Mayo Clinic in Florida · US

Funding

Immunogenetic Mechanisms of Vaccine ResponseR37AI048793 · NIAID · MAYO CLINIC ROCHESTER · PI POLAND, GREGORY A. · 2011 to 2020
$5.4M
Transcriptomic Signatures of Influenza Vaccine ResponsesR01AI132348 · NIAID · MAYO CLINIC ROCHESTER · PI KENNEDY, RICHARD B, POLAND, GREGORY A. · 2018 to 2022
$3.9M
Understanding measles vaccine failure (and success) in Southern IndiaR01AI121054 · NIAID · MAYO CLINIC ROCHESTER · PI JACOB, JOSHY, KENNEDY, RICHARD B · 2017 to 2021
$3.8M
Genetic Markers of Long-Term Mumps Vaccine ImmunityR01AI127365 · NIAID · MAYO CLINIC ROCHESTER · PI KENNEDY, RICHARD B · 2016 to 2020
$3.6M
NIAID NIH HHS R01 AI121054NIAID NIH HHS R01 AI127365NIAID NIH HHS R01 AI132348NIAID NIH HHS R37 AI048793
6 · The paper itself

Abstract

This article provides a review of studies evaluating the role of host (and viral) genetics (including variation in HLA genes) in the immune response to coronaviruses, as well as the clinical outcome of coronavirus-mediated disease. The initial sections focus on seasonal coronaviruses, SARS-CoV, and MERS-CoV. We then examine the state of the knowledge regarding genetic polymorphisms and SARS-CoV-2 and COVID-19. The article concludes by discussing research areas with current knowledge gaps and proposes several avenues for future scientific exploration in order to develop new insights into the immunology of SARS-CoV-2.

Indexed as

Genetic Predisposition to DiseaseAnimalsBetacoronavirusCoronavirus InfectionsCOVID-19Disease ResistanceHost-Pathogen InteractionsHumansMiddle East Respiratory Syndrome CoronavirusPandemicsPneumonia, ViralSARS-CoV-2Severe Acute Respiratory SyndromeSevere acute respiratory syndrome-related coronavirusallelescoronavirusCOVID-19genesgenetic variationgenome-wide association studyGWASHLAimmunogeneticspolymorphismsSARSSARS-CoV-2severe acute respiratory syndromesingle nucleotidesystems biologyvaccine

Identifiers

PMID32658335
PMCPMC7404857
OpenAlexW3041470702

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.